Back

Effectiveness of nirmatrelvir-ritonavir against hospital admission: a matched cohort study in a large US healthcare system

2022-10-04 epidemiology Title + abstract only
View on medRxiv
Show abstract

BackgroundIn the United States, oral nirmatrelvir-ritonavir (Paxlovid) is authorized for use among patients aged [≥]12 years with mild-to-moderate SARS-CoV-2 infection who are at risk for progression to severe COVID-19, including hospitalization. However, effectiveness under current real-world prescribing practices in outpatient settings is unclear. MethodsWe undertook a matched observational cohort study of non-hospitalized cases with SARS-CoV-2 infection to compare outcomes among those who...

Predicted journal destinations